How Much Does the Shingles Vaccine Cost?

Updated on August 30, 2026 | Written by Alec Pow
This article was researched using 10 sources. See our methodology and corrections policy.

The shingles vaccine, Shingrix, costs $0 out of pocket for Medicare Part D beneficiaries and is also available for $0 to most people with private insurance when received according to their plan’s preventive-vaccine rules. If you are paying without insurance, the CDC’s July 2026 private-sector vaccine-price benchmark is $242.667 per dose, while current retail-price data from SingleCare puts the average cash price around $354.81 per dose.

Shingrix requires two doses for the recommended series. That puts the vaccine-product cost at approximately $485.33 for two doses using the CDC private-sector benchmark, or about $709.62 using SingleCare’s current average retail cash price. SingleCare currently advertises a discount price as low as $252.73 per dose, which would reduce two doses to about $505.46. Pharmacy prices, discount eligibility, and provider charges can differ.

There is no longer a current Shingrix-versus-Zostavax price decision in the United States. Zostavax has not been available in the U.S. since November 18, 2020. CDC currently recommends the two-dose Shingrix vaccine for adults age 50 and older and for adults age 19 and older who are or will be immunocompromised because of disease or treatment.

Article Highlights

• Medicare Part D beneficiaries pay $0 out of pocket for the recommended shingles vaccine.
• Most privately insured patients also pay $0 when Shingrix is obtained under the plan’s applicable in-network preventive-vaccine coverage.
• The CDC’s July 2026 private-sector Shingrix benchmark is $242.667 (at $30 per hour, earning that amount would take about 1 full-time workday, before taxes) per dose, or $485.33 for two doses.
• SingleCare currently reports an average uninsured retail price of $354.81 per dose, or $709.62 for the full two-dose series.
• A current SingleCare discount can reduce the price to as little as $252.73 per dose, or approximately $505.46 for two doses.
• Shingrix is the only shingles vaccine currently available in the United States. Zostavax was discontinued from the U.S. market in 2020.
• CDC recommends two doses for adults age 50+ and immunocompromised adults age 19+.

How Much Does the Shingles Vaccine Cost?

Coverage or price benchmark	Cost per dose	Two-dose cost
Medicare Part D	$0	$0
Most qualifying private insurance	$0	$0
Most qualifying Medicaid coverage	$0	$0
CDC July 2026 private-sector benchmark	$242.667 (about 1 full-time workday at $30 per hour)	$485.33
Current SingleCare discount example	$252.73	$505.46
Current SingleCare average retail cash price	$354.81	$709.62

The current CDC Adult Vaccine Price List gives Shingrix a private-sector cost of $242.667 per dose. That is a useful national product-price benchmark, but it is not a promise that an uninsured patient will be charged exactly $242.67 at a pharmacy or medical office.

Current consumer pricing illustrates the difference. SingleCare’s Shingrix pricing page, updated August 30, 2026, reports an average retail price of $354.81 for one dose and a discount price as low as $252.73. Prices vary by pharmacy and location.

The Two-Dose Cost

Shingrix is not a one-shot vaccination for people following the standard recommendation. Two doses are required.

ThePricer math shows how much the price source matters.

At the CDC private-sector benchmark:

$242.667 (about 1 full-time workday at $30 per hour) × 2 = $485.334, or approximately $485.33 for the series.

At SingleCare’s current average cash-retail figure:

$354.81 × 2 = $709.62.

At its current lowest advertised discount:

$252.73 × 2 = $505.46.

The difference between average retail and that discount is $204.16 for the two-dose series.

The much larger financial difference comes from insurance. Someone paying the current $354.81 average retail figure twice would spend $709.62. A Medicare Part D beneficiary receiving the covered vaccine pays $0. That makes checking coverage before paying cash potentially worth more than $700.

Medicare Pays $0

Current Medicare coverage rules are much simpler than older shingles-vaccine cost guides suggest.

If you have Medicare Part D drug coverage, you pay $0 for an ACIP-recommended shingles vaccination. Medicare specifically says Part D plans cannot apply a copayment or deductible to these recommended adult vaccines.

That means old examples in which a patient first paid a $200 vaccine bill toward a Part D deductible and then paid coinsurance for dose two are obsolete.

Traditional Medicare Part A and Part B are not the primary coverage route for Shingrix. The vaccine falls under Medicare drug coverage. A Medicare Advantage plan that includes Part D prescription coverage can provide the same applicable vaccine benefit.

It is still worth checking where the plan wants the vaccine administered. Pharmacy and medical-office billing systems do not always process Part D claims in exactly the same way.

Private Insurance and Medicaid

Most people with qualifying private health insurance can also receive Shingrix without paying a deductible, copayment, or coinsurance when the vaccine is delivered under the plan’s applicable preventive-care rules.

HealthCare.gov explains that most health plans cover preventive services, including recommended immunizations, without cost sharing when the service is received from an appropriate in-network provider. Coverage details and exceptions can still vary.

GSK currently says 96% of privately insured patients pay $0 for Shingrix. Because that figure comes from the vaccine manufacturer, the patient’s own insurer should remain the final authority on a specific claim.

Medicaid coverage also improved substantially compared with older cost guides. Medicaid.gov states that most adult Medicaid beneficiaries must have coverage for approved ACIP-recommended adult vaccines without cost sharing.

The practical question is therefore often not “What percentage of this $250 vaccine will my insurer pay?” It is “Can I receive it for $0 if I use the correct covered provider or pharmacy?”

Shingrix Is the Current Vaccine

Older articles often compare Shingrix with Zostavax. That is no longer a current U.S. purchasing decision.

The CDC’s current shingles vaccination guidance says Zostavax has not been available for use in the United States since November 18, 2020.

Shingrix, formally called recombinant zoster vaccine, is the currently available shingles vaccine. The FDA lists it for prevention of shingles in adults age 50 and older and in adults age 18 and older who are at increased risk because of immunodeficiency or immunosuppression.

CDC recommends two doses for:

• Adults age 50 and older
• Adults age 19 and older who are or will be immunocompromised because of disease or therapy

This second category is especially important. Immunocompromised adults should not generally be described as people who automatically need to avoid Shingrix. Current CDC guidance specifically recommends vaccination for qualifying immunocompromised adults age 19 and older.

When the Second Dose Is Due

For most adults age 50 and older, CDC recommends the second Shingrix dose 2 to 6 months after the first.

For some immunocompromised adults who would benefit from completing the series more quickly, CDC says dose two can be given 1 to 2 months after dose one.

The current CDC Shingrix dosing recommendations also answer a common question about missed appointments. If more than six months have passed since the first dose, the series does not need to be restarted. The second dose should be administered as soon as appropriate.

This matters financially too. Missing the six-month window does not normally mean paying for another dose one and starting the entire series over.

What the Vaccine Prevents

Shingles occurs when varicella-zoster virus, the same virus responsible for chickenpox, becomes active again later in life. CDC estimates about one in three people in the United States will develop shingles during their lifetime.

One of the most important complications is postherpetic neuralgia, or PHN, which can cause persistent nerve pain long after the rash resolves.

CDC reports that Shingrix was 97% effective against shingles among healthy adults ages 50 to 69 in clinical studies and 91% effective among healthy adults age 70 and older.

Among adults with weakened immune systems, effectiveness against shingles ranged from approximately 68% to 91% depending on the underlying condition.

Those effectiveness figures are medical outcomes rather than financial guarantees. They help explain why Shingrix is an ACIP-recommended preventive vaccine and why federal insurance rules frequently reduce the patient’s price to $0.

Readers comparing other adult immunization costs can also see our current guides to flu shot costs, yellow fever vaccination, and human rabies shots.

Side Effects and Safety

Price is not the only consideration when scheduling two doses. Shingrix commonly causes temporary reactions as the immune system responds.

CDC lists common effects including arm pain, redness or swelling at the injection site, fatigue, muscle pain, headache, chills, fever, stomach discomfort, and nausea. These effects usually resolve in approximately 2 to 3 days.

The FDA also requires a warning concerning Guillain-Barré syndrome. Its Shingrix safety communication says a postmarketing observational study found an increased risk of GBS during the 42 days following vaccination. FDA said the available evidence showed an association but was insufficient to establish a causal relationship.

CDC says Shingrix should not be given to someone with a history of a severe allergic reaction to the vaccine or one of its components, someone currently experiencing shingles, or during pregnancy. People with specific medical circumstances should discuss timing with their healthcare professional.

The Hidden Cash-Price Gap

The biggest hidden cost is paying cash before verifying insurance.

Consider three people receiving the same two-dose Shingrix series:

• Medicare Part D: approximately $0 total out of pocket for the covered vaccine.
• Current SingleCare discount: approximately $505.46 for two doses.
• Current average retail cash price: approximately $709.62 for two doses.

The medical product is the same, but the difference between $0 and $709.62 comes from coverage and how the claim is processed.

Before paying cash, ask the insurer or pharmacy whether Shingrix is covered at $0, whether the location is in-network, and whether the claim needs to run through the medical or prescription-drug benefit.

For uninsured patients who cannot afford the vaccine, GSK operates patient assistance programs that can provide certain GSK vaccines at no cost to eligible patients. Eligibility rules apply and assistance is not guaranteed.

When to Check Coverage First

Makes sense if:

• You have Medicare Part D and want to confirm the pharmacy can process the vaccine at $0.
• You have private insurance and can use an in-network pharmacy or provider.
• You have Medicaid and want to confirm the plan’s participating vaccination locations.
• You are uninsured and want to compare the pharmacy’s cash price with discount programs before paying.
• You received dose one months ago and need to verify when dose two should be given.

Does not make sense if:

• You pay a $250 to $350+ cash price before checking whether insurance covers the vaccine at $0.
• You compare Shingrix with Zostavax as though both are currently sold in the United States.
• You assume being immunocompromised automatically means Shingrix is contraindicated.
• You restart the vaccine series solely because more than six months passed after dose one without first checking current CDC guidance.
• You rely on an old Medicare deductible or coinsurance example from before the current vaccine cost-sharing rules.

What We Checked

• Checked the CDC’s July 2026 adult vaccine price list and confirmed the Shingrix private-sector benchmark of $242.667 per dose.
• Verified directly with Medicare that Part D beneficiaries pay $0 for the ACIP-recommended shingles vaccine.
• Cross-referenced current private-insurance preventive-care requirements and GSK coverage data before describing $0 private coverage.
• Confirmed current Medicaid rules covering recommended adult vaccines without cost sharing for most beneficiaries.
• Verified current CDC recommendations for adults age 50+ and immunocompromised adults age 19+.
• Checked current retail and discount pricing dated August 30, 2026 before calculating the uninsured two-dose totals.

Answers to Common Questions

How much does the shingles vaccine cost without insurance?
The CDC’s July 2026 private-sector Shingrix benchmark is $242.667 per dose. Current SingleCare data puts the average retail cash price at approximately $354.81 per dose, with a discount price as low as $252.73. Actual pharmacy prices vary.

How much do both Shingrix doses cost?
At the CDC private-sector benchmark, two doses equal approximately $485.33. At SingleCare’s current average retail price, the two-dose total is around $709.62. Many insured patients pay $0.

Is the shingles vaccine free with Medicare?
Yes, if you have Medicare Part D drug coverage, Medicare says you pay $0 for the ACIP-recommended shingles vaccine with no vaccine copayment or deductible.

Is Shingrix free with private insurance?
It often is. Marketplace plans and many other private plans cover recommended preventive vaccinations without cost sharing when the applicable coverage and network requirements are met. GSK says 96% of privately insured patients currently pay $0.

Do I need one or two shingles shots?
CDC recommends two Shingrix doses. For most adults, dose two is given 2 to 6 months after dose one. Some immunocompromised adults can receive dose two after 1 to 2 months when a shorter schedule is medically appropriate.

What if I waited more than six months for my second Shingrix dose?
CDC says not to restart the series. The second dose should be given as soon as appropriate.

Can immunocompromised adults get Shingrix?
Yes. CDC recommends two doses for adults age 19 and older who are or will be immunodeficient or immunosuppressed because of disease or therapy. Timing may need to be coordinated with the clinician managing the underlying condition or treatment.

Can I still get Zostavax instead because it is cheaper?
No. Zostavax has not been available for use in the United States since November 18, 2020. Shingrix is the current shingles vaccine used under CDC recommendations.